About
Incisive Technologies is a medical device company focussed on empowering oral healthcare professionals and increasing the opportunity for preventative treatments globally.
Founded in 2012, Incisive’s lead technology leverages research from The University of Melbourne and the Melbourne Dental School into the cause and treatment of Molar Incisor Hypomineralisation (MIH known as chalky teeth), this prompted the researchers to wonder ‘how proteins could be harnessed as biomarkers to find the porous regions in enamel (hydroxyapatite)’. The team’s discovery led to an understanding that protein has a high affinity for porous enamel (Mangum, 2010), which is the fundamental definition of caries and the precursor to dental cavities. The team’s research focussed on understanding enamel decay with the aim of improving clinical outcomes for patients. This research into the detection of caries lesions lead to development of the lead technology and granted patents, including 22 jurisdictions across Americas, Europe and the Asia-Pacific.
Company growth has been significant in recent years, facilitated by a successful partnership with CareQuest Innovation Partners (Boston), the leading dental advocacy group in the US, and an AusIndustry Accelerating Commercialisation and Industry Growth Program (IGP) grants. These have propelled Incisive's towards translation, scale-up readying for commercialisation and entry into the US Market following FDA 510k Clearance in May 2023.
BlueCheck is the first product to be commercialised by Incisive Technologies. We are committed to advancing improved caries management and will continue to work with leading clinicians and academics to support the drive towards prevention and minimally invasive care. Incisive has a number of research and collaboration projects to understand BlueCheck’s role in clinical management and how it can make early caries detection simple.
The US market is our first launch market, representing a sizable opportunity, with over 225 million routine dental check-ups per annum. We are building our US team to support bringing BlueCheck to market and driving the evolution of oral care. We are always looking for talent with a shared passion to advancing oral healthcare to address the global challenge of tooth decay.
“We’ve worked directly with dentists, orthodontists, collaborators and experienced investors to understand how novel technologies can support the shift to better care and improve patient outcomes. Early detection of dental caries and the differentiation of their activity status are keys to success and de-risk the challenges with caries diagnosis. BlueCheck gives the clinician objective evidence in detecting and monitoring early caries. Our aim is to help simplify the management of caries, by enabling prevention.”
Early 2023, we launched our new medical device manufacturing facility in Melbourne, Australia. This purpose-built facility, designed and constructed with key partners CBE Pure Solutions and BioConstruct, aligns with Incisive’s values, supporting direct manufacture, to expand the value chain and keep capabilities locally in Australia.